MedTrace Logo

Optimization of Treatment Priority of the Manchester Triage System

NCT05473988 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 77976

Last updated 2023-05-03

No results posted yet for this study

Summary

In the emergency department, the urgency for treating patients is determined according to the Manchester Triage System. The parameters collected in this process are deterministically translated into a treatment priority.

The Manchester Triage System (MTS), which has been in use for at least 20 years, is a widely used, validated and standardized procedure for initial assessment in the emergency department - this initial assessment (triage) is done to prioritize medical assistance at a central point. Especially in emergency situations, critically endangered patients often require the deployment of a large part of the available staff at the same time - the medically correct triage of patients according to objective criteria in order to enable an adequate allocation of the available resources at the right time is the main objective. In the optimal case, each patient is treated by medical professionals within the time frame that is adequate for his/her health condition.

Using artificial intelligence methods, it may be possible to increase the accuracy of treatment priority assignment. In the best case, incorrect prioritization of patients can be prevented and medical care can be ensured for those patients who actually need it most urgently.

However, initial assessment, even if standardized and validated, still runs under limited resource conditions - time, space, material and personnel. Last but not least, the very idea of conducting an initial assessment limits its validity, and the results of the allocation fluctuate according to current research, although the determinants of this are currently unknown.

Conditions

  • Triage

Interventions

OTHER

Admission to General Ward

Admission to General Ward

OTHER

Admission to Intensive Care Unit

Admission to Intensive Care Unit

OTHER

30 Day Mortality

30 Day Mortality

Sponsors & Collaborators

  • Kepler University Hospital

    lead OTHER

Principal Investigators

  • Thomas Tschoellitsch, MD · Kepler University Hospital and Johannes Kepler University, Linz, Austria

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2022-07-31
Completion
2022-07-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05473988 on ClinicalTrials.gov